Cosmetic and Skin Peptides in Research: GHK-Cu, KPV and the GLOW Blend

Cosmetic and skin peptides sit at an odd intersection of real, decades-old biochemistry and modern marketing that regularly outruns the data. GHK-Cu has legitimate in vitro and ex vivo research behind it going back to the 1980s. KPV has a genuinely elegant anti-inflammatory mechanism, studied mostly in a completely different organ than the one it is marketed for. GLOW and KLOW are catalogue blends built by combining individually studied peptides, not compounds that have themselves been through any study. This article works through what the published literature actually supports for each of these, names the specific claims that do not hold up, and links out to the site's deeper single-peptide research pieces for anyone who wants the full dose-by-dose breakdown.

What "Skin Peptide" Research Actually Covers

Under one loose marketing umbrella, "skin peptides" or "cosmetic peptides" in the research-supply world usually means a handful of distinct compounds with very different evidence bases:

GHK-Cu, a copper-binding tripeptide with the most substantial in vitro and ex vivo literature of the group, mostly around collagen synthesis, growth-factor expression and skin penetration. KPV, an anti-inflammatory tripeptide derived from alpha-MSH, whose strongest data comes from mouse gut-inflammation models rather than skin. And two combination products, GLOW and KLOW, which bundle GHK-Cu with wound-and-regeneration peptides BPC-157 and TB-500 (and, in KLOW, KPV) into a single vial. None of these compounds are approved cosmetic drugs or medicines in the EU or US. They are sold and studied here as laboratory research materials, and the sections below separate what has actually been measured from what gets repeated as fact without a traceable source.

GHK-Cu: The Best-Studied Copper Peptide in Skin Research

GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine, first identified in human plasma in the 1970s by Loren Pickart. It also occurs naturally in saliva and urine, and its plasma concentration declines with age, from roughly 200 ng/mL around age 20 to roughly 80 ng/mL by age 60 (PMID 35083444). That decline is an association, not proof that restoring GHK levels reverses any aging process in skin or elsewhere; treat it as a correlational data point, not a mechanism of action.

The in vitro collagen data is the oldest and most direct finding in this literature. Maquart and colleagues showed that GHK-Cu stimulates collagen synthesis by cultured human skin fibroblasts in a dose-dependent way, active from 10 to the minus 12 to 10 to the minus 11 molar and maximal at 10 to the minus 9 molar (1 nanomolar) (PMID 3169264). Importantly, the effect reflected more collagen output per cell, not more cells, and the original abstract gives no percentage magnitude for the increase, a detail that gets flattened into vague "boosts collagen production" claims in a lot of secondary content. A related in vivo rat wound-chamber study from the same group found the copper complex increased connective-tissue accumulation in a concentration-dependent way, with collagen stimulation running about twice that of non-collagen protein (PMID 8227353). In a separate line of work, 1 nanomolar GHK-Cu restored population-doubling time toward normal in irradiated human dermal fibroblasts and increased early bFGF and VEGF output versus untreated irradiated controls (PMID 15655171).

Skin penetration is where the picture gets more complicated. Ex vivo diffusion-cell work on human cadaver skin found that 0.68% aqueous GHK-Cu copper does cross the barrier: a permeability coefficient of 2.43 (plus or minus 0.51) times 10 to the minus 4 cm per hour, with 136.2 (plus or minus 17.5) micrograms of copper per square centimeter permeating over 48 hours and 82 (plus or minus 8.1) micrograms per square centimeter retained in the tissue as a depot (PMID 20703511). But a separate microneedle-delivery study reported that, on intact human skin without any delivery enhancement, "almost no peptide or copper permeated," while microneedle pretreatment let roughly 134 nanomoles of peptide and 705 nanomoles of copper through over 9 hours (Li H et al., Pharm Res 2015). Read together, these two datasets say GHK-Cu can cross skin and accumulate there, but mostly when helped along by an enhanced-delivery method, not necessarily from a plain topical application on intact skin.

GHK-Culongevity

Naturally occurring copper tripeptide complex for skin regeneration and anti-aging research. Stimulates collagen synthesis, accelerates wound healing, and modulates 4000+ genes. Plasma levels decline with age, making it a key target in longevity research.

The Human-Evidence Gap and the Conflict-of-Interest Flag

A 2024 pharmacology review put it plainly: there is "a surprising absence of clinical studies" testing GHK or GHK-Cu as an anti-wrinkle ingredient, despite decades of cosmetic marketing use (PMID 39963574). The same review points to GHK-Cu's poor native skin permeability as the likely reason formulators keep reaching for metal-complexation tricks, palmitoylation, microneedling and cell-penetrating-peptide carriers, delivery problems, not proof that the biology itself does not work, but a real gap between mechanism and demonstrated topical effect.

The trial record backs that up. A randomized trial of topical GHK-Cu skincare after CO2 laser resurfacing found no significant objective benefit for erythema or wrinkles versus control, even though patient-reported satisfaction was significantly higher in the GHK-Cu group (PMID 16847171), a disconnect between how a product feels to use and what an objective measurement shows. More strikingly, a rat model of irradiated skin flaps found topical GHK-Cu gel produced a significantly larger ischemic area than control ointment (5.0 versus 3.8 square centimeters, P equals 0.011), with no measurable benefit on vessel number, vessel area or VEGF (PMID 23744835), a clearly negative wound-healing result in that specific model. Against that, a mouse scald-wound study found liposome-encapsulated GHK-Cu increased HUVEC (endothelial cell) proliferation by about 33.1% and produced faster, more vascularized healing than free GHK-Cu (PMID 28370978). The honest summary is that GHK-Cu's effects vary meaningfully by formulation, delivery method and model, not a single clean "it works" or "it doesn't."

There is also a first-ever registered human randomized trial of GHK-Cu, a Phase 2 topical acute-wound-healing study (ClinicalTrials.gov NCT07437586). As of this writing it is only recruiting, with no posted results, so there is still no controlled human efficacy data for GHK-Cu in any indication.

KPV: An Anti-Inflammatory Tripeptide With Thin Skin-Specific Data

KPV (lysine-proline-valine) is the C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (alpha-MSH 11-13). It is reported to retain much of alpha-MSH's anti-inflammatory signaling without activating the melanocortin receptors that drive alpha-MSH's pigmentation and appetite effects, so no tanning or appetite response is expected from KPV itself (PMID 18612139). Mechanistically, KPV is taken up into cells via the PepT1 peptide transporter, and at nanomolar concentrations it inhibits NF-kB activation along with ERK, JNK and p38 MAP-kinase phosphorylation, the core proposed anti-inflammatory pathway (PMID 18061177).

Almost all of the controlled dose-response evidence for that mechanism comes from the gut, not the skin. In mouse DSS- and TNBS-induced colitis models, oral KPV reduced colonic myeloperoxidase activity by roughly 50% (DSS) and roughly 30% (TNBS), reduced weight loss and colon shortening, and lowered pro-inflammatory cytokine expression (PMID 18061177). An independent group reproduced the anti-inflammatory effect in two different colitis models and showed it persists even in mice lacking a functional melanocortin-1 receptor, evidence the effect is at least partly independent of the classical melanocortin pathway (PMID 18092346).

Plain, unformulated KPV also turns out to be poorly bioavailable by the oral route specifically. One nanoparticle-delivery study found a 16 microgram per kilogram per day dose, carried in a hyaluronic-acid nanoparticle, matched the efficacy of free KPV solution given at roughly 12,000-fold higher dose (PMID 28143741). A second, independent group found free oral KPV at 1 mg/kg/day had no measurable benefit at all in mouse colitis, while an engineered prodrug reached higher colonic drug accumulation and did suppress inflammation markers (PMID 41533788). Whether that specific oral-delivery problem generalizes to the subcutaneous or topical routes typically used in research settings is untested and should not be assumed away.

Direct skin-cell evidence for KPV is comparatively thin: mostly in vitro keratinocyte signaling work tied to the broader alpha-MSH pathway (PMID 15102092). No published human clinical trial of KPV exists for any indication, gut or skin, a limitation the site's own KPV research entry states directly after searching PubMed and ClinicalTrials.gov.

KPVregeneration

Anti-inflammatory tripeptide derived from alpha-MSH (positions 11-13). Inhibits NF-kB signaling, supports gut barrier integrity, and shows antimicrobial activity. A targeted approach to inflammation research without broad immunosuppression.

GLOW and KLOW: What Is Actually in the Blends, and What Is Not Tested

GLOW is a three-peptide blend combining GHK-Cu, BPC-157 and TB-500. KLOW is the same combination plus KPV, four peptides total. A direct PubMed search for this specific combination, run for this article, returned zero studies testing the blend itself as a formulated product. Everything written above about GHK-Cu and KPV individually, including the negative results and the human-evidence gap, applies to their behavior as isolated compounds. There is no published combination-level efficacy, dosing or interaction data for GLOW or KLOW as sold.

Vendor listings for KLOW typically describe an 80 milligram total vial as roughly 50 milligrams GHK-Cu, 10 milligrams BPC-157, 10 milligrams TB-500 and 10 milligrams KPV. That ratio is a commercial convention that varies by vendor and carries no clinical or pharmacological validation behind it; it is a recipe, not a studied formulation.

It is also worth being clear-eyed about the other two components. BPC-157's evidence base is overwhelmingly preclinical rat data, concentrated in work from largely one research group, with no completed human efficacy trial. TB-500 and its parent molecule thymosin beta-4 have the strongest human data of the group through the RGN-259 dry-eye trials, but that program is small and mixed: the 2025 Phase 3 SEER-3 trial missed its primary corneal-healing endpoint, and a separate 2025 human cardiac trial of thymosin beta-4 was overall negative on infarct size. So two of the four peptides that make up GLOW and KLOW themselves carry thin or mixed human data, on top of the blend never having been tested together at all.

GLOWregeneration

3-in-1 skin peptide blend: GHK-Cu 50mg + BPC-157 10mg + TB-500 10mg. Targets collagen synthesis, tissue regeneration, and skin repair for comprehensive dermatological research.

KLOWregeneration

4-in-1 anti-aging peptide blend: GHK-Cu 50mg + BPC-157 10mg + TB-500 10mg + KPV 10mg. Targets collagen synthesis, tissue regeneration, skin repair, and anti-inflammatory pathways.

BPC-157regeneration

Gastric pentadecapeptide (15 amino acids) known for exceptional tissue repair properties. Promotes wound healing, angiogenesis, and cytoprotection across tendons, muscles, gut, and nerves. Over 30 years of preclinical research.

Is There Human Evidence for Cosmetic Peptides at All?

Not much, and what exists is narrower than the marketing suggests. The one real human RCT connected to this peptide family used copper-free GHK combined with a separate compound, 5-aminolevulinic acid, not GHK-Cu, and reported hair-count improvements in men with pattern hair loss (PMID 27489425), a hair result, not a skin-cosmetic one, and not attributable to GHK-Cu alone since it tested a combination product. For KPV, the human-trial count across all indications is zero. For BPC-157 and TB-500, the strongest human program (RGN-259, dry eye) had a mixed 2025 outcome. None of this means the underlying peptides are without mechanistic interest, GHK-Cu's collagen and growth-factor signaling and KPV's NF-kB inhibition are both real, repeatedly observed cell-culture findings, it means the leap from "interesting in vitro or rodent finding" to "works the same way applied to human skin" has not been made yet for any peptide in this group.

A related, frequently confused compound is AHK-Cu, alanyl-histidyl-lysine-copper, structurally distinct from GHK-Cu by one amino acid and studied mainly for hair rather than skin: ex vivo human hair follicles and dermal papilla cells responded to AHK-Cu at picomolar-to-nanomolar concentrations (PMID 17703734), a dataset frequently mislabeled online as GHK-Cu evidence. For the full breakdown of that naming confusion and the older rodent hair-follicle literature, see our dedicated GHK-Cu hair follicle research article, and for a route-of-administration comparison (topical versus injectable), see GHK-Cu topical versus injectable in skin research. For a side-by-side look at GHK, GHK-Cu and AHK-Cu as three related but distinct molecules, see GHK vs GHK-Cu vs AHK-Cu.

Healing & Regenerationregeneration

Tissue repair, wound healing, and recovery peptides

This article is for informational and educational purposes only. All peptides discussed are intended exclusively for laboratory research and are not for human consumption.